INmune Bio Co-Founder and Chief Scientific Officer Mark Lowdell, PhD, Delivers Keynote at CTERP International Conference
12 avr. 2018 10h05 HE
|
INmune Bio, Inc.
LA JOLLA, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company developing therapies that reprogram the patient’s innate immune system to treat cancer, announces...
Hitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
12 avr. 2018 09h00 HE
|
OmniSeq
BUFFALO, N.Y., April 12, 2018 (GLOBE NEWSWIRE) -- OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation...
Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients
10 avr. 2018 07h00 HE
|
Rich Pharmaceuticals
BEVERLY HILLS, CA , April 10, 2018 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc. (OTC: RCHA), a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology,...
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
02 avr. 2018 10h20 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 02, 2018 (GLOBE NEWSWIRE) --
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that...
Karmanos Cancer Institute, first cancer center in Michigan to offer CAR-T Therapy for an aggressive type of non-Hodgkin Lymphoma
27 mars 2018 08h05 HE
|
Barbara Ann Karmanos Cancer Institute
DETROIT, March 27, 2018 (GLOBE NEWSWIRE) -- The Barbara Ann Karmanos Cancer Institute in Detroit is the first center in Michigan approved to treat adult patients with diffuse large B-cell...
INmune Bio’s Professor Mark Lowdell to Participate as Expert Speaker at the Third Annual Innate Killer Summit 2018
26 mars 2018 08h30 HE
|
INmune Bio, Inc.
LA JOLLA, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- via NetworkWire - INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune...
eFFECTOR Announces Appointment of John W. Smither to its Board of Directors
23 mars 2018 14h00 HE
|
eFFECTOR Therapeutics
SAN DIEGO, March 23, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced the...
CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody
22 mars 2018 09h34 HE
|
Crown Bioscience
SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...
Todos Medical reports on results of clinical trials for its blood test for breast cancer screening (TM - B1) conducted at Kaplan Hospital in Rehovot, Israel
22 mars 2018 08h00 HE
|
Todos Medical Ltd.
REHOVOT, Israel, March 22, 2018 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTC Pink:TOMDF) (http://www.Todosmedical.com) today announced the results of a clinical trial recently completed at Kaplan...
Innovest Global Inc. Signs Letter of Intent to Acquire 20% of StemVax Therapeutics, a Biotechnology & Health Sciences Company
19 mars 2018 08h00 HE
|
Innovest Global, Inc
CLEVELAND, March 19, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC PINK: IVST) announces it has signed a Letter of Intent to acquire a 20% stake in StemVax LLC. StemVax is a Translational...